Current Report Filing (8-k)
26 July 2022 - 06:47AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of
1934
July 20, 2022
Date of Report (date of earliest event reported)
ANGION BIOMEDICA CORP.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
|
|
|
|
|
|
Delaware
|
001-39990 |
11-3430072
|
|
(State or other jurisdiction of incorporation or
organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
|
|
|
|
|
|
|
|
|
51 Charles Lindbergh Boulevard |
|
|
|
Uniondale, New York 11553 |
|
|
|
(Address of Principal Executive Offices including zip
code)
|
|
|
(415) 655-4899
Registrant's telephone number, including area code
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐ Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
|
|
|
|
|
|
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common Stock |
ANGN |
The Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act.o
Item 2.05 Costs associated with Exit or Disposal
Activities
On July 20, 2022, Angion committed to and commenced a reduction in
force that will impact the majority of Angion’s current 37
employees. Angion’s decision to engage in this reduction results
from Angion’s Board of Director's determination to commence a
process to explore and pursue strategic options to enhance and
preserve shareholder value. At this time, Angion is discontinuing
development of ANG-3070 for all indications and discontinuing most
other development activities pending conclusion of the strategic
process. The reduction in force is a cash preservation measure and
impacts employees across the organization.
Angion expects to record a charge of approximately $2.9 million in
the third quarter of 2022 to implement the reduction in force,
which is expected to conclude in October of 2022. These charges are
primarily one-time termination benefits in cash.
Item
5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers
As
part of Angion's reduction in force, John F. Neylan, M.D., EVP,
Chief Medical Officer and Head of Research, will depart Angion
effective August 15, 2022. Dr. Neylan has served as Angion's Chief
Medical Officer since December of 2018. Dr. Neylan is eligible to
receive severance benefits under Angion’s Amended and Restated
Executive Severance Plan, dated November 19, 2021, filed as an
exhibit to Angion’s Form 10-K on March 30, 2022.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, as amended, the Registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly
authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ANGION BIOMEDICA CORP. |
|
|
|
|
|
|
|
|
|
By: |
|
/s/ Jay R. Venkatesan |
Date: July 25, 2022 |
|
|
|
|
Jay R. Venkatesan, M.D.
President and Chief Executive Officer and
|
Angion Biomedica (NASDAQ:ANGN)
Historical Stock Chart
From Mar 2023 to Apr 2023
Angion Biomedica (NASDAQ:ANGN)
Historical Stock Chart
From Apr 2022 to Apr 2023